A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab

INTRODUCTION: Plaque psoriasis and hidradenitis suppurativa are chronic inflammatory skin conditions with common pathogenetic pathways. METHODS: We report the case of a 38-year-old man with 15-year history of psoriasis and hidradenitis suppurativa successfully treated with tildrakizumab for both con...

Descripción completa

Detalles Bibliográficos
Autor principal: Damsin, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307742/
https://www.ncbi.nlm.nih.gov/pubmed/37266889
http://dx.doi.org/10.1007/s13555-023-00940-0
_version_ 1785066100523794432
author Damsin, Thomas
author_facet Damsin, Thomas
author_sort Damsin, Thomas
collection PubMed
description INTRODUCTION: Plaque psoriasis and hidradenitis suppurativa are chronic inflammatory skin conditions with common pathogenetic pathways. METHODS: We report the case of a 38-year-old man with 15-year history of psoriasis and hidradenitis suppurativa successfully treated with tildrakizumab for both conditions. After treatment failure to adalimumab, secukinumab, and guselkumab, tildrakizumab therapy was initiated and resulted in complete remission of psoriasis and the achievement of hidradenitis suppurativa clinical response after 40 weeks, without reporting adverse events. These responses were maintained at week 52. CONCLUSION: Tildrakizumab may be an effective and safe therapeutic option for concomitant psoriasis and hidradenitis suppurativa.
format Online
Article
Text
id pubmed-10307742
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-103077422023-06-30 A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab Damsin, Thomas Dermatol Ther (Heidelb) Case Report INTRODUCTION: Plaque psoriasis and hidradenitis suppurativa are chronic inflammatory skin conditions with common pathogenetic pathways. METHODS: We report the case of a 38-year-old man with 15-year history of psoriasis and hidradenitis suppurativa successfully treated with tildrakizumab for both conditions. After treatment failure to adalimumab, secukinumab, and guselkumab, tildrakizumab therapy was initiated and resulted in complete remission of psoriasis and the achievement of hidradenitis suppurativa clinical response after 40 weeks, without reporting adverse events. These responses were maintained at week 52. CONCLUSION: Tildrakizumab may be an effective and safe therapeutic option for concomitant psoriasis and hidradenitis suppurativa. Springer Healthcare 2023-06-02 /pmc/articles/PMC10307742/ /pubmed/37266889 http://dx.doi.org/10.1007/s13555-023-00940-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Damsin, Thomas
A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
title A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
title_full A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
title_fullStr A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
title_full_unstemmed A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
title_short A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
title_sort case of concurrent psoriasis and hidradenitis suppurativa successfully treated with tildrakizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307742/
https://www.ncbi.nlm.nih.gov/pubmed/37266889
http://dx.doi.org/10.1007/s13555-023-00940-0
work_keys_str_mv AT damsinthomas acaseofconcurrentpsoriasisandhidradenitissuppurativasuccessfullytreatedwithtildrakizumab
AT damsinthomas caseofconcurrentpsoriasisandhidradenitissuppurativasuccessfullytreatedwithtildrakizumab

Ejemplares similares